Traders Sell Shares of Bristol-Myers Squibb Company (BMY) on Strength (BMY)
Investors sold shares of Bristol-Myers Squibb Company (NYSE:BMY) on strength during trading hours on Thursday. $188.05 million flowed into the stock on the tick-up and $262.40 million flowed out of the stock on the tick-down, for a money net flow of $74.35 million out of the stock. Of all stocks tracked, Bristol-Myers Squibb had the 0th highest net out-flow for the day. Bristol-Myers Squibb traded up $2.97 for the day and closed at $62.84
A number of brokerages have commented on BMY. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Credit Suisse Group restated a “hold” rating on shares of Bristol-Myers Squibb in a research report on Friday. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Vetr downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $64.20 price target for the company. in a report on Thursday. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $66.00 price target (up previously from $63.00) on shares of Bristol-Myers Squibb in a report on Thursday, August 24th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $62.54.
The firm has a market cap of $102.69 billion, a PE ratio of 22.87 and a beta of 1.18. The company’s 50 day moving average price is $57.53 and its 200 day moving average price is $55.70.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.69 EPS. Equities analysts anticipate that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Theodore R. Samuels II bought 6,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were acquired at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the purchase, the director now owns 18,000 shares in the company, valued at $1,006,920. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the business. Tradewinds Capital Management LLC grew its stake in Bristol-Myers Squibb by 34.6% during the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 500 shares in the last quarter. Atlantic Trust LLC purchased a new position in Bristol-Myers Squibb during the 2nd quarter valued at about $111,000. Welch Investments LLC grew its stake in Bristol-Myers Squibb by 3.9% during the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 79 shares in the last quarter. Crestwood Advisors Group LLC purchased a new position in Bristol-Myers Squibb during the 1st quarter valued at about $116,000. Finally, Blue Chip Partners Inc. grew its stake in Bristol-Myers Squibb by 0.8% during the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 17 shares in the last quarter. 68.80% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This report was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/09/09/traders-sell-shares-of-bristol-myers-squibb-company-bmy-on-strength-bmy-4.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.